Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to improve the lives of cancer patients. They generate revenue primarily through the sale of their FDA-approved drug, QINLOCK, which treats gastrointestinal stromal tumors (GIST). Founded in 2003, Deciphera has a rich history of leveraging its proprietary kinase switch control inhibitor platform to create targeted therapies. The company is headquartered in Waltham, Massachusetts, and continues to advance its robust pipeline of drug candidates through clinical trials.

Recent Posts by Deciphera Pharmaceuticals

1-20 of 47